港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

526.439

+13.6662.67%

漲家數：24

跌家數：5

平家數：4

市盈率：- -

高：540.538

開：513.718

低：513.718

收：512.773

成交量：9,398.61萬

成交額：34.88億

市值：3,372.30億

流通市值：2,995.25億

資料載入中...

總覽新聞資訊

沛嘉醫療-B(09996)中報觀：核心AR產品放量超預期，盈利信號鞏固投資確定性

德琪醫藥ATG-201（CD19 x CD3 TCE）B細胞相關自身免疫疾病I期ATTRACT研究獲澳大利亞臨床試驗批准

中國生物製藥減重「貼片」新藥在美國獲批臨床；益方生物重啓港股上市申請｜醫藥早參

每日经济新闻

德琪醫藥-B(06996)：ATG-201用於治療由B細胞介導的自身免疫性疾病的I期ATTRACT研究在澳大利亞獲HREC批准

《業績》榮昌生物(09995.HK)中期純利46.62億人民幣虧轉盈

阿斯达克财经

4600億市值醫藥巨頭遭遇網絡安全事件 A股公司同類事件已非個案

每日经济新闻

騰盛博藥-B(02137)8月24日斥資6.03萬港元回購6萬股

mRNA賽道迎歷史性突破，雲頂新耀自研價值凸顯

天府财经网

和譽-B(02256)：建議中文雙重外文名稱更改為「和譽醫藥有限責任公司」

加科思-B(01167)發布中期業績，股東應占收益6.01億元按年扭虧為盈

創新藥突然啞火，什麼原因？華寶基金港股通創新藥ETF再失半年線，CXO龍頭盡墨，機構:四季度繼續看好醫藥

總投資3800萬！河南一改建年產200噸醫藥中間體項目

全球創新藥產業景氣上行，國內創新藥出海步入「豐收大年」

創新藥、算力硬件產業鏈大幅回調，創業板指跌超3%｜華寶基金3A日報（2026.8.24）

諾誠健華(09969)公布中期業績經調整利潤約2.77億元按年扭虧為盈

榮昌生物：上半年淨利潤46.62億元，按年扭虧為盈

老虎资讯综合

跨行拿下56億大單，這家會做生意的公司，成配置創新藥首選？

CXO與創新藥協同共振步入收穫季，借港股通創新藥ETF嘉實一鍵佈局全產業鏈

A股收評：創業板指跌超3%，醫藥、算力硬件股齊挫，貴金屬逆勢走強！

恒瑞醫藥半年報解讀：高投入難換高增長昔日「醫藥一哥」增收難增利

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/BK1574/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":526.4386,"timestamp":1787716798925,"preClose":512.7729,"halted":0,"volume":93986122,"delay":0,"changeRate":0.026651,"floatShares":0,"shares":0,"eps":0,"marketStatus":"午間休市","change":13.66571,"latestTime":"08-26 12:00:00","open":513.7177,"high":540.53845,"low":513.7177,"amount":3488302757,"amplitude":0.052305,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1787720400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787707800000,1787716800000],[1787720400000,1787731200000]],"pbRate":3.84011,"peRate":154.066227,"turnoverRate":0.003412,"increases":24,"decrements":5,"flats":4,"marketCap":337230403184,"floatMarketCap":299524986480},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":540.53845,"amplitude":0.052305,"preClose":512.7729,"low":513.7177,"pbRate":"3.84011","latestPrice":526.4386,"volume":93986122,"delay":0,"open":513.7177,"prevYearClose":556.26263,"prevWeekClose":506.075,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":492.831,"twentyDayClose":481.996,"sixtyDayClose":519.865,"secType":"PLATE","market":"HK","turnoverRate":0.003412,"peRate":154.066227,"marketCap":337230403184,"floatMarketCap":299524986480,"timestamp":1787716798925,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":24,"down":5,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662320278","title":"沛嘉醫療-B(09996)中報觀：核心AR產品放量超預期，盈利信號鞏固投資確定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2662320278","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662320278?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 08:56","pubTimestamp":1787619374,"startTime":"0","endTime":"0","summary":"智通财经APP了解到，8月21日，沛嘉医疗披露了其2026年中期业绩。财报显示，公司在报告期内实现总收入4.25亿元，同比增长20.1%。TAVR产品持续放量，AR表现显著超预期今年上半年，沛嘉医疗凭借自身更高的销售效率和研发效率，进一步巩固了公司作为中国瓣膜介入治疗领域头部品牌的地位。凭借差异化产品设计、安全性及标准化术式，TaurusTrio上市后快速获得临床认可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AR","09996","159891","BK1100","BK1574","METV","LNGX","BK4213","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128345154","title":"德琪醫藥ATG-201（CD19 x CD3 TCE）B細胞相關自身免疫疾病I期ATTRACT研究獲澳大利亞臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1128345154","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128345154?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 08:31","pubTimestamp":1787617871,"startTime":"0","endTime":"0","summary":"德琪医药宣布，其在澳大利亚开展的ATG-201用于治疗B细胞相关自身免疫疾病的I期ATTRACT研究，已正式获得临床试验批准。ATG-201的设计初衷在于精准靶向并清除致病性B细胞，从而有望为系统性红斑狼疮、类风湿性关节炎等一系列B细胞驱动的自身免疫疾病患者带来全新的治疗选择。公司计划尽快启动患者招募，并期待ATG-201能够释放潜力，改写自身免疫疾病的治疗格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","06996","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662204818","title":"中國生物製藥減重「貼片」新藥在美國獲批臨床；益方生物重啓港股上市申請｜醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2662204818","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662204818?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 07:03","pubTimestamp":1787612588,"startTime":"0","endTime":"0","summary":"丨2026年8月25日星期二丨NO.1中国生物制药GLP-1减重“贴片”新药在美国获批临床中国生物制药宣布CPX301可溶微针获美国FDA临床试验默示许可，拟用于体重管理。CPX301是中国生物制药核心企业北京泰德制药研发的GLP-1受体激动剂可溶微针贴片，具有给药便捷、递送高效、无菌安全、储运便利的特点，有望为需要长期体重管理的人群提供一种新的给药选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608253851708095.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608253851708095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","HK0000165453.HKD","VXUS","01177","IE00BZ08YS42.EUR","BK1574","159938","IE00BZ08YT58.USD","BK1191","BK4585","BK4588","BK1521","BK1589","IE00BZ08YR35.GBP","IPOS","BK1515","09939","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201084","title":"德琪醫藥-B(06996)：ATG-201用於治療由B細胞介導的自身免疫性疾病的I期ATTRACT研究在澳大利亞獲HREC批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201084","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201084?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 07:00","pubTimestamp":1787612436,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布公告，本公司董事会欣然宣布，集团自主研发的ATG-201(一种用于治疗B细胞相关自身免疫性疾病的CD19/CD3双特异性T细胞衔接抗体)的I期ATTRACT研究，已获得澳大利亚人类研究伦理委员会(HREC)批准，并已完成向治疗用品管理局(TGA)提交临床试验通知(CTN)的程序。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484743.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06996","BK1191","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662220378","title":"《業績》榮昌生物(09995.HK)中期純利46.62億人民幣  虧轉盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2662220378","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662220378?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 02:47","pubTimestamp":1787597220,"startTime":"0","endTime":"0","summary":"荣昌生物(09995.HK) 公布6月止六个月中期业绩，收益58.5亿人民币(下同)，按年增加435.7%。录得纯利46.62亿元，相较上年同期亏损4.5亿元，亏转盈；每股盈利8.32元。不派息。(d)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-24 16:25。)过往派息公布日期派息事项派息内容2026/04/28第一季业绩无派息2026/03/27末期业绩无派息2025/10/30第三季业绩无派息2025/08/22中期业绩无派息AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210305144102705_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210305144102705_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1540424/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1540424/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["CYB","LU2328871848.SGD","LU1064130708.USD","BK1574","BK0239","LU1064131003.USD","LU1969619763.USD","LU2148510915.USD","CNHmain","LU2488822045.USD","688331","MUCmain","MCNHmain","BK1161","UCmain","09995","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662270285","title":"4600億市值醫藥巨頭遭遇網絡安全事件 A股公司同類事件已非個案","url":"https://stock-news.laohu8.com/highlight/detail?id=2662270285","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662270285?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 00:19","pubTimestamp":1787588349,"startTime":"0","endTime":"0","summary":"8月24日盘后，药明康德（603259.SH，股价155.84元，市值4650亿元）发布《自愿性公告》，披露其生物学业务板块的DNAEncodedLibrary平台（DEL平台）近期遭遇一起网络安全事件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608253851657324.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608253851657324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IHAK","02846","WCBR","FDIF","83188","LOUP","FWD","BK1161","09939","BUG","INVN","TEKX","BK4588","PSWD","FDFF","NBDS","UCYB","CRTC","159982","EIS","XT","02827","ANEW","SKYY","82846","CRWC","USMD","NSI","07233","DRES","159938","03188","03130","399300","TEKY","FITE","GSFP","MVPS","SPAM","BPAY","BK1574","TEK","PSCT","BCTK","KOMP","CIBR","CRWL","HAKY","83130","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661272579","title":"騰盛博藥-B(02137)8月24日斥資6.03萬港元回購6萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661272579","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661272579?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 22:32","pubTimestamp":1787581951,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B(02137)发布公告，于2026年8月24日，该公司斥资6.03万港元回购6万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1161","BK1574","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661272296","title":"mRNA賽道迎歷史性突破，雲頂新耀自研價值凸顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2661272296","media":"天府财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661272296?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 22:28","pubTimestamp":1787581680,"startTime":"0","endTime":"0","summary":"消息公布后，Moderna股价大幅上涨，mRNA肿瘤免疫赛道随之升温。Moderna的临床突破，确立了其在mRNA肿瘤疫苗领域的先发优势，但当前这一赛道远非终局。值得注意的是，近日，云顶新耀发布了2026年中期业绩。mRNA平台作为其自主研发体系的重要支柱，有望在肿瘤免疫新时代持续释放增长动能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-24/doc-inipmsvk1961020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","BK1583","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271402","title":"和譽-B(02256)：建議中文雙重外文名稱更改為「和譽醫藥有限責任公司」","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271402","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271402?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 21:30","pubTimestamp":1787578215,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，和誉开曼有限责任公司董事会建议将本公司的英文名称由“Abbisko Cayman Limited”更改为“Abbisko Medicine Co., Ltd.”，并将本公司的中文双重外文名称由“和誉开曼有限责任公司”更改为“和誉医药有限责任公司”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","LU2488822045.USD","BK1161","LU2778985437.USD","IE00B5MMRT66.SGD","02256","LU2476274720.SGD","BK1574","IE00B543WZ88.USD","159938","LU2476274308.USD","IE00BPRC5H50.USD","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661527918","title":"加科思-B(01167)發布中期業績，股東應占收益6.01億元 按年扭虧為盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2661527918","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661527918?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 20:48","pubTimestamp":1787575700,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布截至2026年6月30日止6个月中期业绩，该集团取得收入7.31亿元，同比增加1500.5%;公司拥有人应占收益6.01亿元，去年同期则取得亏损5899.4万元;每股基本盈利0.78元。公告称，收入增长主要由于就 JAB-23E73的全球研发、生产及商业化与AstraZeneca AB进行的战略合作;及就艾瑞凯®及sitneprotafib的研发、生产及商业化与艾力斯订立的对外许可及服务协议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01167","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275244","title":"創新藥突然啞火，什麼原因？華寶基金港股通創新藥ETF再失半年線，CXO龍頭盡墨，機構:四季度繼續看好醫藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275244","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275244?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:48","pubTimestamp":1787572080,"startTime":"0","endTime":"0","summary":"8月24日，港股深度调整，近期热度较高的医药板块同步走低。100%创新药研发标的——港股通创新药ETF华宝日线连阴，收于半年线下方，全天振幅3.44%，成交3.18亿元。值得一提的是，截至上周，159137在CXO带动连续5周收涨。全链布局创新药，关注两大T+0利器：港股通创新药ETF华宝：被动跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，7成仓位押注研发龙头。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-24/doc-inipmnps2837356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","BK1161","BK1515","159316","09939","BK1574","06978","159992","FLHK","CXO","WX","MEDX","159938","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661278278","title":"總投資3800萬！河南一改建年產200噸醫藥中間體項目","url":"https://stock-news.laohu8.com/highlight/detail?id=2661278278","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661278278?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 18:35","pubTimestamp":1787567700,"startTime":"0","endTime":"0","summary":"近日，河南科来福化工有限公司年产200吨医药中间体项目在相关网站第二次公示。项目概述项目名称：河南科来福化工有限公司年产200吨医药中间体项目建设单位：河南科来福化工有限公司建设地点：开封精细化工开发区总 投 资：投资3800万元占地面积：该项目利用现有的厂房和附属设施进行建设，项目总占地49亩生产规模：建设一条年产200吨N-[-2-[1，1’-联苯]-4-基-1-乙基]氨基甲酸叔丁酯产品的生产线；对现有的200t/a甲酮生产线进行升级改造。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-24/doc-inipmnpn1922077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1161","BK1574","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661278967","title":"全球創新藥產業景氣上行，國內創新藥出海步入「豐收大年」","url":"https://stock-news.laohu8.com/highlight/detail?id=2661278967","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661278967?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 18:33","pubTimestamp":1787567600,"startTime":"0","endTime":"0","summary":"中国创新药产业在全球创新药生态中崛起之际，参与二级市场优质标的的投资，分享产业成长机遇至关重要。　　近期，多家海外MNC与CXO披露中报盈喜并上调2026年全年指引。　　创新药产业链方面，CDMO与CRO订单、收入及盈利表现持续改善。中国创新药出海BD持续加速，已经BD产品逐步进入海外实质性兑现期，未来几年将","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/24/20260824404702.jpeg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/24/20260824404702.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260824/32345072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IBBQ","BK1161","LNGR","159992","MEDX","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661227577","title":"創新藥、算力硬件產業鏈大幅回調，創業板指跌超3%｜華寶基金3A日報（2026.8.24）","url":"https://stock-news.laohu8.com/highlight/detail?id=2661227577","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661227577?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 17:44","pubTimestamp":1787564640,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-24/doc-inipmhfp0033689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","03147","LNGR","BK1574","399001","07234","06978","399006","BK1161","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661853227","title":"諾誠健華(09969)公布中期業績 經調整利潤約2.77億元 按年扭虧為盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2661853227","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661853227?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 17:39","pubTimestamp":1787564375,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华 公布2026年中期业绩，收益约11.37亿元，同比增长55.46%;经调整利润约2.77亿元，同比扭亏为盈;母公司拥有人应占溢利约2.46亿元，同比扭亏为盈。于报告期内，诺诚健华进一步推进其多产品、多领域的战略，在血液肿瘤、自身免疫性疾病及实体瘤领域的贡献持续扩大。随着多项产品商业化或即将提交监管申请，诺诚健华已迈入多元化增长的新阶段，不仅提升了盈利可预测性，更扩大全球业务布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484265.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688428","BK1574","BK1161","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177027604","title":"榮昌生物：上半年淨利潤46.62億元，按年扭虧為盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1177027604","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177027604?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 17:31","pubTimestamp":1787563888,"startTime":"0","endTime":"0","summary":"8月24日，$荣昌生物(09995)$公告，2026年上半年营业收入58.53亿元，同比增长433.11%；归属于上市公司股东的净利润46.62亿元，2025年同期亏损4.5亿元，实现扭亏为盈；归属于上市公司股东的扣除非经常性损益的净利润43.38亿元，2025年同期亏损4.46亿元。","market":"sh","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"72e3de9ba94345e5a6a76224eeec6cd3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荣昌生物：上半年净利润46.62亿元，同比扭亏为盈","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","688331","LU1064130708.USD","LU1969619763.USD","LU2148510915.USD","BK1574","BK1161","09995","LU1064131003.USD","LU2488822045.USD","BK0239","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661224776","title":"跨行拿下56億大單，這家會做生意的公司，成配置創新藥首選？","url":"https://stock-news.laohu8.com/highlight/detail?id=2661224776","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661224776?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 17:05","pubTimestamp":1787562308,"startTime":"0","endTime":"0","summary":"甘李药业一季报的十大股东名单上，机构早已做了针对性布局。　　近几个月，在A股二级市场上，创新药赛道再次上演加速上行的好戏，从而一举奠定了非科技板块中领军者的地位。特别是8月14日盘中，股价最高达到79.99元，创出了年内以来的新高。　　从背后原因看，最直接的是公司和欧洲某著名药企签下了总金额高达7.26亿欧元的大单，此前其截至2025年9月的研发投入大约是6.85亿元人民币。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/24/20260824491543.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/24/20260824491543.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260824/32344982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IBBQ","BK1161","LNGR","159992","MEDX","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661922977","title":"CXO與創新藥協同共振步入收穫季，借港股通創新藥ETF嘉實一鍵佈局全產業鏈","url":"https://stock-news.laohu8.com/highlight/detail?id=2661922977","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661922977?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 16:07","pubTimestamp":1787558820,"startTime":"0","endTime":"0","summary":"多家尚未登陆 A 股的创新药、CXO 龙头汇聚港股市场，普通投资者想要把握这一轮产业机遇，或可锚定覆盖港股创新药全产业链、CXO含量较高的港股通创新药ETF嘉实及其联接基金来一键布局。如果场内投资者想高效把握港股创新药和CXO龙头的高景气，港股通创新药ETF嘉实或更适配，其支持场内T+0交易，投资效率更高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-08-24/doc-inipkzxs2033792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","IBBQ","LNGR","BK1161","159992","06978","520970","CXO","MEDX","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661229354","title":"A股收評：創業板指跌超3%，醫藥、算力硬件股齊挫，貴金屬逆勢走強！","url":"https://stock-news.laohu8.com/highlight/detail?id=2661229354","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661229354?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 15:36","pubTimestamp":1787556987,"startTime":"0","endTime":"0","summary":"全市场超3900只个股下跌","market":"fut","thumbnail":"https://img7.gelonghui.com/column/2/101.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/101.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6255104","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1147","399006","83130","399001","LU1993786604.SGD","82846","000001","83188","BK0278","DBP","LU0880133367.SGD","LU1781817850.SGD","LU0501845795.SGD","02827","07234","BK0028","LU0072913022.USD","IE00B0JY6N72.USD","BK1161","09939","BK0012","LU1580142542.USD","BK0183","YSAG","BK0187","LU1226287529.USD","LU0067412154.USD","03188","03147","07233","159982","LU1655091616.SGD","BK1515","BK0188","399300","BK1574","03130","LU1807302812.USD","02846","BK0201","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661293262","title":"恒瑞醫藥半年報解讀：高投入難換高增長   昔日「醫藥一哥」增收難增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2661293262","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661293262?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 15:17","pubTimestamp":1787555820,"startTime":"0","endTime":"0","summary":"2026年8月，恒瑞医药正式对外披露半年报，这份被市场寄予厚望的中期成绩单，未能延续行业对“创新药龙头复苏高增长”的预期。上半年总营收154.56亿元，同比2025年同期157.61亿元下滑1.9%，出现阶段性半年度营收负增长。证监会黑龙江监管局处罚文书显示，恒瑞医药前董事长周云曙在职期间，利用行业合作内幕信息交易司太立股票，违法获利45万元，监管部门2025年9月作出处罚，没收全部违法所得并处50万元罚款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-08-24/doc-inipkzxr0043463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1580142542.USD","LU2097828474.EUR","LU0405327494.USD","LU1997245177.USD","LU2097828631.EUR","BK0188","LU1781817850.SGD","BK1574","LU1820825898.SGD","LU1969619763.USD","LU1064131003.USD","LU2543165471.USD","BK1161","LU0405327148.USD","600276","LU1655091616.SGD","LU0359202008.SGD","LU2097828805.USD","LU2580892862.HKD","BK0028","LU1146622755.USD","LU2148510915.USD","LU2488822045.USD","LU1064130708.USD","BK0196","BK0060","LU2097828714.EUR","BK0239","BK1515","159938","BK1191","LU1023057109.AUD","LU2097828557.USD","BK0012","LU2580892789.USD","BK0183","01276","LU1328615791.USD","LU1997244956.HKD","LU1997245094.SGD","LU0359201612.USD","LU0359201885.HKD","LU2495084118.USD","LU1255011170.USD","LU2328871848.SGD","09939","LU2289578879.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":19,"pageCount":4,"totalSize":379,"code":"91000000","status":"200"}]}}